Product image of Methylfenidaat Retard Eg (Methylphenidate Hydrochloride) supplied by GNH India

Methylfenidaat Retard Eg

Active Ingredient:
Methylphenidate Hydrochloride
Origin:
EU

Methylfenidaat Retard Eg (Methylphenidate Hydrochloride)

Methylphenidate, the active ingredient in Methylfenidaat Retard Eg, is a central nervous system stimulant presented as an extended‑release tablet for oral administration. It is indicated for the management of attention deficit hyperactivity disorder (ADHD) and narcolepsy across pediatric, adolescent, and adult populations.

GNH India supplies Methylfenidaat Retard Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality compliance with EU standards and reliable distribution channels. The company provides comprehensive support for regulatory documentation and cold‑chain logistics where required.

Manufacturer / TM Owner

Eurogenerics N.V./S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Methylphenidate acts on central nervous system neurotransmitter pathways to improve attention and wakefulness.

  • Attention deficit hyperactivity disorder (ADHD): improves concentration, reduces hyperactivity and impulsivity.
  • Narcolepsy: decreases excessive daytime sleepiness and improves alertness.
  • Attention deficit disorder (ADD): supports sustained attention and reduces distractibility in patients diagnosed with ADD.

How It Works

  • Methylphenidate inhibits the reuptake of dopamine and norepinephrine by blocking their transporters, leading to increased synaptic concentrations of these catecholamines. The heightened neurotransmitter activity enhances neuronal firing in brain regions responsible for attention, impulse control, and wakefulness, thereby producing its therapeutic effects in ADHD and narcolepsy.

Side Effects

Methylfenidaat Retard Eg may cause a range of adverse reactions, some of which are more frequently observed than others.

Common Side Effects

  • Insomnia: difficulty falling or staying asleep.
  • Decreased appetite: reduced hunger leading to potential weight loss.
  • Headache: mild to moderate cranial pain.
  • Stomach pain: gastrointestinal discomfort or nausea.

Serious or Rare Side Effects

  • Cardiovascular events: chest pain, hypertension, or arrhythmia.
  • Psychosis or severe mood changes: hallucinations, delusions, or manic episodes.
  • Severe allergic reaction: rash, swelling, or anaphylaxis.

Precautions & Warnings

Before prescribing Methylfenidaat Retard Eg, clinicians should consider several safety aspects.

  • Cardiovascular assessment: evaluate blood pressure and heart rate prior to initiation.
  • Psychiatric history: review for prior psychosis, bipolar disorder, or severe anxiety.
  • Substance misuse: assess risk of abuse or dependence.
  • Concomitant medications: check for drugs that may increase blood pressure or interact with stimulant pathways.
  • Pregnancy and lactation: discuss potential risks and benefits with the patient.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Avoid Interactions

Methylfenidaat Retard Eg can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

  • Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis.
  • Antihypertensive agents: may reduce blood‑pressure‑lowering effect.
  • Antipsychotics (e.g., haloperidol): can diminish stimulant response.

Moderate Interactions (Monitor Closely)

  • Selective serotonin reuptake inhibitors (SSRIs): may increase serotonergic activity.
  • Tricyclic antidepressants: potential additive cardiovascular effects.
  • Alcohol or caffeine: can exacerbate stimulant‑related side effects such as insomnia or tachycardia.

Frequently Asked Questions

Methylfenidaat Retard Eg contains methylphenidate and is prescribed for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It helps improve focus, reduce hyperactivity, and maintain wakefulness in patients diagnosed with these conditions.

Methylphenidate blocks the reuptake of dopamine and norepinephrine, increasing their levels in the synaptic cleft. This elevation enhances neurotransmission in brain areas that regulate attention, impulse control, and alertness, providing therapeutic benefit for ADHD and narcolepsy.

The specific dose of Methylfenidaat Retard Eg is determined by the prescribing clinician based on the patient’s age, condition severity, and response to therapy. Dosage adjustments are made according to individual therapeutic needs and tolerability.

Methylfenidaat Retard Eg is classified as Pregnancy Category C, indicating that risk cannot be ruled out. It should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should discuss possible infant exposure with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Methylfenidaat Retard Eg is an extended‑release stimulant, offering once‑daily dosing and a smoother plasma concentration profile compared with immediate‑release formulations. Compared with non‑stimulant options, it generally provides a more rapid onset of action but may carry a higher risk of cardiovascular and psychiatric side effects.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and keep out of reach of children.

Methylfenidaat Retard Eg is taken orally as an extended‑release tablet. It should be swallowed whole with water, preferably in the morning, and not crushed, chewed, or broken, to maintain the intended release profile.

Serious risks include cardiovascular events such as hypertension or arrhythmia, severe psychiatric reactions like psychosis or mania, and rare allergic reactions that may lead to anaphylaxis. Patients should be monitored closely for any signs of these conditions.

Methylfenidaat Retard Eg is contraindicated in individuals with known hypersensitivity to methylphenidate, those taking monoamine oxidase inhibitors, patients with severe cardiovascular disease, and anyone with a history of serious psychiatric disorders where stimulants may exacerbate symptoms.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.